Literature DB >> 25107498

Systolic blood pressure, choroidal thickness, and axial length in patients with myopic maculopathy.

Chih-Chien Hsu1, Shih-Jen Chen2, An-Fei Li3, Fenq-Lih Lee3.   

Abstract

BACKGROUND: In the population-based Shihpai Eye Study, patients aged >65 years with myopic maculopathy were found to have higher systolic blood pressure. This finding deserved further exploration because this is the only correctable factor for preventing maculopathy in patients with high myopia. Therefore, we investigated the association between myopic maculopathy and systolic blood pressure, as well as other ocular parameters in this study.
METHODS: A clinic-based, retrospective cross-sectional study at a medical center was conducted between February 2011 and October 2012. Patients with high myopia were included and medical charts were reviewed. High myopia was defined as axial length ≥26.5 mm in at least one eye. Myopic maculopathy was defined as the presence of lacquer cracks, focal areas of deep choroidal atrophy, diffuse chorioretinal atrophy, and macular choroidal neovascularization or geographic atrophy in the presence of high myopia. Systolic blood pressure measurements were collected, and fundus photography and optical coherence tomography were performed. Subfoveal choroidal thickness (SFCT) shown on optical coherence tomography was measured and recorded.
RESULTS: The medical records of 187 high-myopic patients (87 without and 100 with maculopathy) were reviewed. Patients with maculopathy were older (56.96 years vs. 42.95 years, p < 0.01), had longer axial length (29.96 mm vs. 27.31 mm, p < 0.01), thinner SFCT (49.71 μm vs. 155.77 μm, p < 0.01), higher systolic blood pressure (132.28 mmHg vs. 125.31 mmHg, p < 0.05), greater prevalence of hypertension (31% vs. 16%, p < 0.05), and longer history of hypertension (2.34 years vs. 0.59 years, p < 0.01) compared to patients without maculopathy. After multivariate adjustment, SFCT and axial length were the only significant factors for maculopathy.
CONCLUSION: Thinner SFCT and longer axial length are significant risk factors for myopic maculopathy. Unlike previous epidemiological surveys, results of this clinic-based study suggested that systolic blood pressure is not a significant factor for maculopathy.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  axial length; choroidal thickness; high myopia; hypertension; myopic maculopathy

Mesh:

Year:  2014        PMID: 25107498     DOI: 10.1016/j.jcma.2014.06.009

Source DB:  PubMed          Journal:  J Chin Med Assoc        ISSN: 1726-4901            Impact factor:   2.743


  5 in total

1.  Abnormal Functional Connectivity Between Cerebral Hemispheres in Patients With High Myopia: A Resting FMRI Study Based on Voxel-Mirrored Homotopic Connectivity.

Authors:  Yi Cheng; Xiao-Lin Chen; Ling Shi; Si-Yu Li; Hui Huang; Pei-Pei Zhong; Xiao-Rong Wu
Journal:  Front Hum Neurosci       Date:  2022-06-23       Impact factor: 3.473

2.  Characterization of Brain Microstructural Abnormalities in High Myopia Patients: A Preliminary Diffusion Kurtosis Imaging Study.

Authors:  Huihui Wang; Hongwei Wen; Jing Li; Qian Chen; Shanshan Li; Yanling Wang; Zhenchang Wang
Journal:  Korean J Radiol       Date:  2021-05-04       Impact factor: 3.500

3.  Computational Approach to Investigating Key GO Terms and KEGG Pathways Associated with CNV.

Authors:  YuanYuan Luo; Yan Yan; Shiqi Zhang; Zhen Li
Journal:  Biomed Res Int       Date:  2018-04-11       Impact factor: 3.411

4.  Cerebral Blood Flow Alterations in High Myopia: An Arterial Spin Labeling Study.

Authors:  Huihui Wang; Shanshan Li; Xi Chen; Yanling Wang; Jing Li; Zhenchang Wang
Journal:  Neural Plast       Date:  2020-01-09       Impact factor: 3.599

5.  Prevalence and risk factors of myopic maculopathy: a cross-sectional study in Han and Uygur adults in Xinjiang, China.

Authors:  Ting Chen; Jin Ma; Guang-Liang Shan; Lize Pa; Lin Ding; Li Pan; Limujiang Ke; Hebuli Mu; Senjiang Ya; Ning Tao; Fen Dong; Ke Wang; Yong Zhong
Journal:  BMJ Open       Date:  2020-11-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.